ClinicalTrials.gg
CompletedNCT02867098Updated Dec 8, 2017

XmAb5871 Bioavailability Study

A Phase 1 interventional study of XmAb5871 in Healthy Volunteers, sponsored by Xencor, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

An open label comparison of concentration of the study medication administered intravenously (IV) versus subcutaneously (SC) in healthy volunteers.

Read the detailed description

The study will enroll approximately 50 eligible healthy male and female subjects between the ages of 18 to 55 inclusive. There will be 5 parallel dose cohorts (Cohorts 1-5) consisting of 10 subjects in each cohort. No subject will be a member of more than 1 cohort. Subjects will receive 3 administrations of study medication.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy
  • volunteer
03

In context

Lead sponsor

Xencor, Inc. is the lead sponsor of 30 studies on the registry; 7 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 2 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are adult males and females aged 18 to 55 years inclusive as of dosing (Day 1) with total body weight between 45.0 and 100.0 kg inclusive and (BMI) between 19.0 and 32.0 kg/m2 inclusive;
  • Healthy as assessed by the Investigator with no abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;

Exclusion criteria

Exclusion Criteria:

  • Subjects who have a history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Subjects who are positive for drugs of abuse or alcohol on screening or admission;
  • Subject is pregnant or breast feeding, or planning to become pregnant within 3 months of administration of XmAb5871.
  • Subjects who have used prescription drugs (with the exception of hormonal for women of ) within 14 days or 5 half-lives, whichever is longer, prior to dosing (Day 1), unless agreed as not clinically relevant by the Principal Investigator and Sponsor.
  • Subjects who have received ≤3 months from Day 1.
  • within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin).
  • Unable or unwilling to partake in follow-up assessments or required protocol procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Dose Level 1 XmAb5871 given SC Q14days X 3

    Drug: XmAb5871

  • Experimental
    Cohort 2

    Dose Level 2 XmAb5871 given SC Q14days X 3

    Drug: XmAb5871

  • Experimental
    Cohort 3

    Dose Level 3 XmAb5871 given SC Q14days X 3

    Drug: XmAb5871

  • Experimental
    Cohort 4

    Dose Level 4 XmAb5871 given IV Q14days X 3

    Drug: XmAb5871

  • Experimental
    Cohort 5

    Dose Level 5 XmAb5871 given SC Q7days X 3

    Drug: XmAb5871

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax, Maximum observed serum concentration

    Time frame: Date of enrollment to Day 57

  2. Tmax, Time of maximum observed serum concentration

    Time frame: Date of enrollment to Day 57

  3. AUC, Area under the plasma concentration versus time curve

    Time frame: Date of enrollment to Day 57

  4. CL, Clearance of drug from the body

    Time frame: Date of enrollment to Day 57

  5. Vz, Volume of distribution

    Time frame: Date of enrollment to Day 57

  6. F, bioavailability of a SC dose relative to an IV dose

    Time frame: Date of enrollment to Day 57

  7. Number of participants with adverse events that are related to treatment

    Time frame: Date of enrollment to Day 57

  8. Number of participants with severe adverse events that are related to treatment

    Time frame: Date of enrollment to Day 57

  9. Number of participants with abnormal laboratory values related to treatment

    Time frame: Date of enrollment to Day 57

  10. Number of participants with abnormal ECGs related to treatment

    Time frame: Date of enrollment to Day 57

Secondary outcomes

  1. Titers of anti-XmAb5871 antibody will be assessed from time of dosing up to Day 57

    Time frame: Date of enrollment to Day 57

  2. Percent of participants positive in the assay at at least one time point

    Time frame: Date of enrollment to Day 57

  3. Percent of participants with increasing titers of anti-drug antibody over time

    Time frame: Date of enrollment to Day 57

07

Study locations

1 site
  • PAREXEL, Early Phase Clinical Unit-Los Angeles
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Oct 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2016
First posted
Aug 15, 2016
StartActual
Jul 2016
Primary completionActual
Oct 21, 2016
CompletionActual
Oct 21, 2016
Last update
Dec 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02867098
Lead sponsor
Xencor, Inc.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 15, 2016
Start date
Jul 2016
Primary completion
Oct 21, 2016
Completion
Oct 21, 2016
Last update
Dec 8, 2017

Study contacts

Esther Yoon, MD
principal investigator · California Clinical Trials Medical Group - PAREXEL, Early Phase Clinical Unit-Los Angeles

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion